Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals (Nasdaq: CDT) has received USPTO approval for a composition of matter patent for its lead asset AZD1656, a Glucokinase Activator targeting autoimmune diseases including Lupus and ANCA Vasculitis. The patent grants up to 20 years of market protection in the United States.
The company now holds patent protection in three major pharmaceutical markets - US, Japan, and Australia - with pending applications in Europe and other regions. This positions Conduit for clinical development and strategic partnerships in the U.S. autoimmune disease market, projected to reach $150 billion by 2030.
The targeted conditions affect a significant population, with Lupus impacting 1.5 million Americans and ANCA Vasculitis affecting 200,000 patients annually. The composition of matter patent, classified as a 'drug substance' patent in the FDA's Orange Book, provides strong market exclusivity and protection against generic competition.
Conduit Pharmaceuticals (Nasdaq: CDT) ha ricevuto l'approvazione dell'USPTO per un brevetto di composizione di materia per il suo principale asset AZD1656, un attivatore della glucokinasi che mira a malattie autoimmuni, tra cui il lupus e la vasculite ANCA. Il brevetto conferisce fino a 20 anni di protezione sul mercato negli Stati Uniti.
L'azienda detiene ora la protezione brevettuale in tre importanti mercati farmaceutici - Stati Uniti, Giappone e Australia - con domande pendenti in Europa e in altre regioni. Questo posiziona Conduit per lo sviluppo clinico e partenariati strategici nel mercato delle malattie autoimmuni negli Stati Uniti, previsto raggiungere i 150 miliardi di dollari entro il 2030.
Le condizioni mirate colpiscono una popolazione significativa, con il lupus che interessa 1,5 milioni di americani e la vasculite ANCA che colpisce 200.000 pazienti all'anno. Il brevetto di composizione di materia, classificato come brevetto di 'sostanza medicinale' nel libro arancione della FDA, fornisce una forte esclusività di mercato e protezione contro la concorrenza generica.
Conduit Pharmaceuticals (Nasdaq: CDT) ha recibido la aprobación de la USPTO para una patente de composición de materia para su principal activo AZD1656, un activador de glucocinasa dirigido a enfermedades autoinmunes, incluyendo lupus y vasculitis ANCA. La patente otorga hasta 20 años de protección en el mercado de Estados Unidos.
La empresa ahora posee protección de patente en tres importantes mercados farmacéuticos: EE. UU., Japón y Australia, con solicitudes pendientes en Europa y otras regiones. Esto posiciona a Conduit para el desarrollo clínico y asociaciones estratégicas en el mercado de enfermedades autoinmunes de EE. UU., que se proyecta alcanzará los 150 mil millones de dólares para 2030.
Las condiciones dirigidas afectan a una población significativa, con lupus afectando a 1,5 millones de estadounidenses y vasculitis ANCA afectando a 200,000 pacientes anualmente. La patente de composición de materia, clasificada como patente de 'sustancia farmacéutica' en el libro naranja de la FDA, proporciona una fuerte exclusividad de mercado y protección contra la competencia genérica.
Conduit Pharmaceuticals (Nasdaq: CDT)는 자사의 주요 자산 AZD1656에 대한 물질 조성 특허를 USPTO로부터 승인받았습니다. 이는 루푸스 및 ANCA 혈관염을 포함한 자가면역 질환을 목표로 하는 글루코키나제 활성제입니다. 이 특허는 미국에서 최대 20년간의 시장 보호를 부여합니다.
회사는 이제 미국, 일본, 호주 등 세 가지 주요 제약 시장에서 특허 보호를 보유하고 있으며, 유럽 및 기타 지역에서 신청이 진행 중입니다. 이는 Conduit가 미국 자가면역 질환 시장에서 임상 개발 및 전략적 파트너십을 위한 유리한 위치에 놓이게 합니다. 이 시장은 2030년까지 1,500억 달러에 이를 것으로 예상됩니다.
대상 질환은 상당한 인구에 영향을 미치며, 루푸스는 150만 명의 미국인에게 영향을 미치고 ANCA 혈관염은 매년 20만 명의 환자에게 영향을 미칩니다. 물질 조성 특허는 FDA의 오렌지 북에서 '약물 물질' 특허로 분류되며, 강력한 시장 독점성과 제네릭 경쟁에 대한 보호를 제공합니다.
Conduit Pharmaceuticals (Nasdaq: CDT) a obtenu l'approbation de l'USPTO pour un brevet de composition de matière pour son principal actif AZD1656, un activateur de glucokinase ciblant des maladies auto-immunes, notamment le lupus et la vascularite ANCA. Le brevet accorde jusqu'à 20 ans de protection sur le marché aux États-Unis.
L'entreprise détient désormais une protection par brevet dans trois grands marchés pharmaceutiques - les États-Unis, le Japon et l'Australie - avec des demandes en attente en Europe et dans d'autres régions. Cela positionne Conduit pour le développement clinique et des partenariats stratégiques sur le marché des maladies auto-immunes aux États-Unis, qui devrait atteindre 150 milliards de dollars d'ici 2030.
Les conditions ciblées affectent une population significative, avec le lupus touchant 1,5 million d'Américains et la vascularite ANCA affectant 200 000 patients par an. Le brevet de composition de matière, classé comme un brevet de 'substance médicamenteuse' dans le livre orange de la FDA, offre une forte exclusivité de marché et une protection contre la concurrence générique.
Conduit Pharmaceuticals (Nasdaq: CDT) hat die Genehmigung des USPTO für ein Patent auf eine Stoffzusammensetzung für sein Hauptprodukt AZD1656 erhalten, einen Glukokinase-Aktivator, der auf Autoimmunerkrankungen wie Lupus und ANCA-Vaskulitis abzielt. Das Patent gewährt bis zu 20 Jahre Marktschutz in den Vereinigten Staaten.
Das Unternehmen hat nun Patentschutz in drei wichtigen Pharmamärkten - den USA, Japan und Australien - und hat laufende Anträge in Europa und anderen Regionen. Dies positioniert Conduit für die klinische Entwicklung und strategische Partnerschaften im US-Markt für Autoimmunerkrankungen, der bis 2030 voraussichtlich 150 Milliarden US-Dollar erreichen wird.
Die betroffenen Erkrankungen betreffen eine erhebliche Bevölkerung, wobei Lupus 1,5 Millionen Amerikaner betrifft und ANCA-Vaskulitis jährlich 200.000 Patienten betrifft. Das Patent für die Stoffzusammensetzung, das im Orange Book der FDA als 'Arzneistoff'-Patent eingestuft wird, bietet starke Markt-Exklusivität und Schutz gegen generische Wettbewerber.
- Secured 20-year composition of matter patent protection in the US market
- Patent protection established in three major markets (US, Japan, Australia)
- Targeting large market opportunity ($150B by 2030)
- Strong protection against generic competition through FDA Orange Book listing
- Clinical trials yet to begin
- Patent applications still pending in Europe and other regions
Insights
The USPTO's grant of a composition of matter patent for Conduit's AZD1656 represents a significant milestone that substantially strengthens the company's competitive position. These patents are considered the gold standard in pharmaceutical IP protection, providing the strongest defense against generic competition by protecting the actual molecular structure rather than just its applications or formulations.
With this U.S. approval complementing existing patents in Japan and Australia, Conduit has established an impressive IP fortress across three major pharmaceutical markets. This triple-market protection creates a particularly attractive foundation for potential licensing deals or strategic partnerships, especially with applications pending in Europe and other regions.
The 20-year exclusivity period granted by this composition patent allows Conduit to maximize the commercial potential of AZD1656 within the growing autoimmune disease sector. Such robust IP protection is essential for pharmaceutical companies to justify the substantial investment required for clinical development, which Conduit indicates is now in the final preparation stages.
This patent approval strategically positions the company to potentially capitalize on the $150 billion U.S. autoimmune market projected by 2030, focusing on specific conditions like Lupus and ANCA Vasculitis that affect millions of Americans combined.
This patent approval marks a pivotal inflection point for Conduit Pharmaceuticals' development strategy for AZD1656, their Glucokinase Activator targeting autoimmune conditions. The composition of matter patent—officially classified as a "drug substance" patent in the FDA's Orange Book—provides the critical IP foundation necessary before committing significant resources to the expensive clinical trial process.
The focus on Lupus and ANCA Vasculitis represents a strategic targeting of conditions with substantial unmet needs. Lupus affects approximately 1.5 million Americans while ANCA Vasculitis impacts around 200,000 patients annually—populations large enough to represent meaningful commercial opportunities yet focused enough to potentially allow for more streamlined clinical development programs.
With clinical trial preparations in the final stages, this patent approval removes a significant risk factor that might have otherwise complicated partnership discussions or financing efforts. For a company with Conduit's market capitalization ($5 million), securing such foundational IP assets significantly enhances its ability to pursue the necessary next steps in the drug development pathway.
The patent portfolio's expansion across multiple key pharmaceutical markets (U.S., Japan, Australia) with applications pending elsewhere establishes a global commercial framework that will be essential for maximizing AZD1656's potential value as it progresses through development stages.
- Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that the United States Patent and Trademark Office (USPTO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection now secured, the Company is strategically positioned to advance AZD1656 into clinical development, with clinical trial plans now in final stages of preparation.
The U.S. autoimmune disease market is projected to reach
Composition of matter patents, classified as “drug substance” patents in the U.S. FDA’s Orange Book, represent the gold standard in pharmaceutical intellectual property, providing strong market exclusivity and robust protection against generic competition.
“Securing USPTO approval for AZD1656’s composition of matter patent is a major milestone, further solidifying our intellectual property portfolio and strategic value,” said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. “With the composition of matter patent now in place in this critical market, this also indicates an increased likelihood of patent success in the outstanding additional geographies worldwide.”
About Conduit Pharmaceuticals
Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Investors & Media:
info@conduitpharma.com
FAQ
What is the market potential for CDT's autoimmune disease treatment AZD1656?
How long will CDT's new USPTO patent protect AZD1656 from competition?
In which countries does CDT now have patent protection for AZD1656?
What type of patent protection did CDT receive for AZD1656?
